Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by JT Stratford LLC

JT Stratford LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 39.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,710 shares of the biopharmaceutical company’s stock after selling 1,113 shares during the quarter. JT Stratford LLC’s holdings in Regeneron Pharmaceuticals were worth $961,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in REGN. Cambria Investment Management L.P. grew its stake in Regeneron Pharmaceuticals by 21.8% during the 3rd quarter. Cambria Investment Management L.P. now owns 3,090 shares of the biopharmaceutical company’s stock worth $1,737,000 after buying an additional 554 shares during the last quarter. Skba Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 8.3% in the third quarter. Skba Capital Management LLC now owns 1,298 shares of the biopharmaceutical company’s stock worth $730,000 after acquiring an additional 100 shares in the last quarter. Rock Point Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $214,000. Insigneo Advisory Services LLC increased its holdings in shares of Regeneron Pharmaceuticals by 11.6% during the third quarter. Insigneo Advisory Services LLC now owns 432 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 45 shares in the last quarter. Finally, Cresset Asset Management LLC raised its position in shares of Regeneron Pharmaceuticals by 11.1% in the 3rd quarter. Cresset Asset Management LLC now owns 3,351 shares of the biopharmaceutical company’s stock valued at $1,884,000 after purchasing an additional 336 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $764.93 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The firm has a market cap of $80.87 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 2.12 and a beta of 0.41. The firm’s fifty day moving average is $771.31 and its two-hundred day moving average is $686.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the business posted $12.07 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

REGN has been the topic of several research analyst reports. UBS Group boosted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $796.52.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.